The first in vivo cell atlas of senescent tissue in skeletal muscle has identified the damaging properties of these cells and explained why they block muscle regeneration. According to a study at Pompeu Fabra University led by scientists from Altos Labs Inc., cell damage caused the senescence of the cells, which secreted toxic substances into the surrounding microenvironment, causing fibrosis and preventing tissue regeneration. Read More
Although ovarian cancers appear to be immunologically active, they do not respond well to immunotherapy in the clinic. In a study published on Dec. 14, 2022, in Nature, a multidisciplinary team at Memorial Sloan Kettering Cancer Center (MSK) led by Sohrab Shah and Dmitriy Zamarin has uncovered several mechanisms of immune evasion that can help explain why ovarian cancers have been resistant to immunotherapy to date. Read More
Triple-negative breast cancer (TNBC) has a diverse etiology, with high unmet clinical needs. Researchers from Tavotek Biotherapeutics (Hong Kong) Ltd. presented data on TAVO-412, a trispecific EGFR/cMET/VEGF (2:1:1 binding arm ratio) antibody for the potential treatment of TNBC. Read More
Scientists from the University of Delhi and affiliated organizations have reported the discovery and preclinical characterization of novel compounds with antiplasmodial activity. Read More
RQ Biotechnology Ltd. (RQ Bio) has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD-3152, has entered clinical trials. Read More
Nanjing Kangyi Biomedical Center LP has disclosed compounds with dipyrrolopyridine structure acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of cancer, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and inflammatory bowel disease, among others. Read More
Lunac Therapeutics Ltd. has synthesized coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of arthritis, Alzheimer's disease, disseminated intravascular coagulation, pulmonary embolism, myocardial infarction, diabetic retinopathy, stroke and deep venous thrombosis, among others. Read More
Poolbeg Pharma plc has identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with Onethree Biotech Inc. Read More
Emory University has identified deuterated and/or methylated N4-hydroxycytidine (NHC) analogues reported to be useful for the treatment of viral infections. Read More
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Ethris GmbH has entered into a collaboration with Diosynvax Ltd. to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses utilizing the company's highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. Read More
Korean Research Institute of Bioscience and Biotechnology has described triterpenoid saponins isolated from Spinacia oleracea (spinach) reported to be useful for the treatment of inflammation. Read More
